Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis

Cancer

Volumn 121, Issue 12, 2015, Pages 2083-2089

  O'Neill, Caitriona B ^a,b   Baxi, Shrujal S ^a   Atoria, Coral L ^a   O'Neill, James P ^c   Henman, Martin C ^b   Sherman, Eric J ^a   Lee, Nancy Y ^a   Pfister, David G ^a   Elkin, Elena B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c Panoz Institute   (Ireland)

Author keywords

and End Results (SEER); chemoradiation; Epidemiology; head and neck cancer; Medicare; radiotherapy; Surveillance; toxicity

Indexed keywords

AGED; ANEMIA; ARTICLE; ASPIRATION PNEUMONIA; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; DEEP VEIN THROMBOSIS; DEHYDRATION; DELIRIUM; DIARRHEA; DYSPHAGIA; ESOPHAGITIS; FEEDING APPARATUS; FEMALE; FEVER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART FAILURE; HUMAN; INFECTION; KIDNEY FAILURE; LARYNX CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OROPHARYNX CANCER; POPULATION RESEARCH; PRIORITY JOURNAL; RADIATION INJURY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; VOMITING; ADVERSE EFFECTS; CANCER REGISTRY; COHORT ANALYSIS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEAD AND NECK NEOPLASMS; RADIATION INJURIES; UNITED STATES;

ANTINEOPLASTIC AGENT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; COHORT STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; RADIATION INJURIES; RADIOTHERAPY; SEER PROGRAM; TREATMENT OUTCOME; UNITED STATES;

EID: 84930346552     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29262     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P., Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94: 153-156.
2. American Cancer Society. Cancer Facts & Figures 2012. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2012/. Accessed November 2014.
3. Seiwert TY, Salama JK, Vokes EE., The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol. 2007; 4: 156-171.
4. Michal SA, Adelstein DJ, Rybicki LA, et al., Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly. Head Neck. 2012; 34: 1147-1152.
5. Adelstein DJ, Saxton JP, Rybicki LA, et al., Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol. 2006; 24: 1064-1071.
6. Al-Sarraf M, LeBlanc M, Giri PG, et al., Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998; 16: 1310-1317.
7. Adelstein DJ, Li Y, Adams GL, et al., An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003; 21: 92-98.
8. Pignon JP, Bourhis J, Domenge C, Designe L., Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000; 355: 949-955.
9. Blanchard P, Baujat B, Holostenco V, et al., Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011; 100: 33-40.
10. Brizel DM, Albers ME, Fisher SR, et al., Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998; 338: 1798-1804.
11. Pignon JP, le Maitre A, Maillard E, Bourhis J., Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92: 4-14.
12. Huguenin P, Beer KT, Allal A, et al., Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol. 2004; 22: 4665-4673.
13. Denis F, Garaud P, Bardet E, et al., Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004; 22: 69-76.
14. Forastiere AA, Goepfert H, Maor M, et al., Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349: 2091-2098.
15. Staar S, Rudat V, Stuetzer H, et al., Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001; 50: 1161-1171.
16. Trotti A, Bellm LA, Epstein JB, et al., Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003; 66: 253-262.
17. Trotti A., Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys. 2000; 47: 1-12.
18. Givens DJ, Karnell LH, Gupta AK, et al., Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009; 135: 1209-1217.
19. Machtay M, Moughan J, Trotti A, et al., Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008; 26: 3582-3589.
20. Nwizu T, Ghi MG, Cohen EE, Paccagnella A., The role of chemotherapy in locally advanced head and neck squamous cell carcinoma. Semin Radiat Oncol. 2012; 22: 198-206.
21. Payakachat N, Ounpraseuth S, Suen JY., Late complications and long-term quality of life for survivors (>5 years) with history of head and neck cancer. Head Neck. 2013; 35: 819-825.
22. Bernier J., Current state-of-the-art for concurrent chemoradiation. Semin Radiat Oncol. 2009; 19: 3-10.
23. Riaz N, Sherman EJ, Fury M, Lee N., Should cetuximab replace cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer? J Clin Oncol. 2013; 31: 287-288.
24. Bonner JA, Harari PM, Giralt J, et al., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354: 567-578.
25. Curran D, Giralt J, Harari PM, et al., Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol. 2007; 25: 2191-2197.
26. Baxi SS, O'Neill CB, Sherman EJ, Atoria CL, Lee NY, Pfister DG, Elkin EB,. Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab. Head Neck. 2014; 31 (suppl): 6594.
27. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF., Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40 (suppl): IV-3 -18.
28. Greene FL, Page DL, Fleming ID., AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer Science & Business Media; 2003.
29. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC., Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006; 98: 1108-1117.
30. Hardy D, Liu CC, Cormier JN, Xia R, Du XL., Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Ann Oncol. 2010; 21: 1825-1833.
31. Du XL, Osborne C, Goodwin JS., Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002; 20: 4636-4642.
32. Deyo RA, Cherkin DC, Ciol MA., Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613-619.
33. Charlson ME, Pompei P, Ales KL, MacKenzie CR., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
34. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L., Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck. 2001; 23: 579-589.
35. Merlano M., Alternating chemotherapy and radiotherapy in locally advanced head and neck cancer: an alternative? Oncologist. 2006; 11: 146-151.
36. Murphy BA, Gilbert J., Dysphagia in head and neck cancer patients treated with radiation: assessment, sequelae, and rehabilitation. Semin Radiat Oncol. 2009; 19: 35-42.
37. Harari PM., Promising new advanced in head and neck radiotherapy. Ann Oncol. 2005; 16 (supp 6): vi13-vi19.
38. Locher JL, Bonner JA, Carroll WR, et al., Gastrostomy tube placement and use in patients with head and neck cancer. Head Neck. 2012; 34: 422-428.
39. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG., Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993; 31: 732-748.
40. Potosky AL, Warren JL, Riedel ER, Klabunde CN, Earle CC, Begg CB., Measuring complications of cancer treatment using the SEER-Medicare data. Med Care. 2002; 40: IV-62-8.